Efficacy and safety of sofosbuvir–velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial

BACKGROUND: In Japan, hepatitis C virus (HCV)-infected patients with decompensated cirrhosis currently have no treatment options. In this Phase 3 study, we evaluated sofosbuvir–velpatasvir with or without ribavirin for 12 weeks in patients with any HCV genotype and decompensated cirrhosis [Child–Pug...

Descripción completa

Detalles Bibliográficos
Autores principales: Takehara, Tetsuo, Sakamoto, Naoya, Nishiguchi, Shuhei, Ikeda, Fusao, Tatsumi, Tomohide, Ueno, Yoshiyuki, Yatsuhashi, Hiroshi, Takikawa, Yasuhiro, Kanda, Tatsuo, Sakamoto, Minoru, Tamori, Akihiro, Mita, Eiji, Chayama, Kazuaki, Zhang, Gulan, De-Oertel, Shampa, Dvory-Sobol, Hadas, Matsuda, Takuma, Stamm, Luisa M., Brainard, Diana M., Tanaka, Yasuhito, Kurosaki, Masayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2018
Materias:
Original Article—Liver, Pancreas, and Biliary Tract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314981/
https://www.ncbi.nlm.nih.gov/pubmed/30203225
http://dx.doi.org/10.1007/s00535-018-1503-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314981/
https://www.ncbi.nlm.nih.gov/pubmed/30203225
http://dx.doi.org/10.1007/s00535-018-1503-x

Ejemplares similares